SCHEMBL5828686

SCHEMBL5828686

CC(=O)OC[C@H]1O[C@@H](n2c3ncccc3c3c4c(c5c6cccnc6[nH]c5c32)C(=O)N(COCc2ccccc2)C4=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 1/20 0.40
LMNA P02545 5/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
THRB P10828 1/20 0.40
HIF1A Q16665 1/20 0.40
ALDH1A1 P00352 6/20 0.39
PRKCA P17252 1/20 0.38
AKT1 P31749 1/20 0.38
PTK2 Q05397 1/20 0.38
TGM2 P21980 1/20 0.38
KDM4E B2RXH2 3/20 0.37
HPGD P15428 3/20 0.37
MAPT P10636 3/20 0.37
TSHR P16473 1/20 0.37
PARP1 P09874 1/20 0.35
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAG3 Q9UGI9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5828079 0.94 GALR3 (0.40) GALR3LMNASMN1; SMN2THRBHIF1A
SCHEMBL5828937 0.94 GALR3 (0.40) GALR3LMNASMN1; SMN2THRBHIF1A
SCHEMBL5828420 0.90 LMNA (0.43) GALR3LMNASMN1; SMN2THRBHIF1A
SCHEMBL5828121 0.88 LMNA (0.46) GALR3LMNASMN1; SMN2THRBHIF1A
SCHEMBL5827642 0.84 PRKCA (0.43) GALR3LMNASMN1; SMN2THRBHIF1A
SCHEMBL8769342 0.84 GALR3 (0.40) GALR3LMNASMN1; SMN2THRBHIF1A
SCHEMBL8769931 0.84 GALR3 (0.40) GALR3LMNASMN1; SMN2THRBHIF1A
SCHEMBL5828557 0.84 PRKCA (0.44) GALR3LMNASMN1; SMN2THRBHIF1A
SCHEMBL9083954 0.83 GALR3 (0.39) GALR3LMNASMN1; SMN2THRBHIF1A
SCHEMBL5827662 0.83 PRKCA (0.49) GALR3LMNASMN1; SMN2THRBHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001906-B2 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives LES LABORATOIRES SERVIER (FR) 2006-02-21 US disclosed
US-20040152721-A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives LES LABORATOIRES SERVIER (FR) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152721-A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives PYM1, PNPO, IDO1 GALR3 1515/4885LMNA 4488/4885SMN1; SMN2 4557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.